News
Novo Nordisk slashes price of Ozempic
Digest more
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...
Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...
The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...
6hon MSN
GLP-1 drugs such as Lilly’s Mounjaro and Novo’s Ozempic linked to lower cancer risk: study
Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Novo Nordisk A/S’s slower growth will crimp employee bonuses in the Ozempic maker’s home market of Denmark as it ramps up a ...
Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation – a common heart rhythm condition – in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback